Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema

By Brian Orelli, PhD - Feb 12, 2020 at 5:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drug moves closer to an expanded approval for the skin disorder.

Eli Lilly (LLY 4.12%) and Incyte (INCY 4.56%) are marching forward in their quest to gain regulatory approval for Olumiant as a treatment for atopic dermatitis (AD), commonly referred to as eczema. https://www.globenewswire.com/news-release/2020/02/11/1983486/0/en/Lilly and-Incyte-Announce-Positive-Top-Line-Results-from-the-North-American-Phase-3-Study-BREEZE-AD5-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Patients-with-Moderate-to-Severe.html

Last month, the companies showed that the drug in combination with topical corticosteroids helped patients reduce their eczema symptoms. And now the healthcare companies have demonstrated that the monotherapy is able to help eczema patients as well.

Doctor looking at a patient's arm

Image source: Getty Images.

In the Breeze-AD5 study, 29.5% of patients taking the higher dose of Olumiant had at least a 75% or greater change from baseline in their Eczema Area and Severity Index score (EASI75), compared with 8.2% of patients taking placebo. The lower dose of Olumiant helped 12.9% of patients reach the goal, but the result wasn't statistically better than a placebo.

The higher dose also helped 24% of patients reach clear or almost clear skin, with at least a 2-point improvement on the validated Investigator's Global Assessment for AD, compared with 5.4% of patients taking a placebo. The lower dose helped 12.9% of patients reach the goal, which was statistically better than the placebo result.

A third endpoint that measured itch sensitivity also showed that both doses worked better than a placebo, with the higher dose producing a better result than the lower dose, as expected.

Olumiant is already approved to treat rheumatoid arthritis, but an expansion into eczema would expand the potential market for the drug substantially. Eli Lilly has applied for expanded approval to treat eczema in the EU. With the final clinical trial in the Breeze clinical trial program complete, the company plans to submit marketing applications to expand the approval in the U.S. and Japan this year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$325.62 (4.12%) $12.90
Incyte Corporation Stock Quote
Incyte Corporation
INCY
$78.19 (4.56%) $3.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.